

Adrenal Insufficiency During Prednisolone Treatment

- need for cortisol replacement strategies in patients on long-term low-dose glucocorticoid treatment?

Stina Willemoes Borresen¹, Bo Baslund², Marianne Klose¹, Åse Krogh Rasmussen¹, Lennart Friis-Hansen³, Linda Hilsted³, Henning Locht⁴, Annette Hansen⁵, Merete Lund Hetland⁶, Ulla Feldt-Rasmussen¹

Department of Endocrinology¹, Rheumatology², Clinical Biochemestry³, Rigshospitalet, Department of Rheumatology Frederiksberg Hospital⁴, Gentofte Hospital⁵ and Glostrup Hospital⁶, Copenhagen University Hospital, Denmark



BACKGROUND AND OBJECTIVE

BACKGROUND

- Patients on long-term prednisolone treatment are at risk of adrenal insufficiency during treatment.
- High-dose prednisolone treatment is often sufficient to overcome most stressful situations.
- A low dose of 5 mg prednisolone daily is equivalent to 20 mg hydrocortisone, often used as basal glucocorticoid replacement dose in adrenal insufficiency.
- Contrary to patients in replacement therapy for adrenal insufficiency, patients treated with long-term low-dose prednisolone for various reasons are often not instructed in self-administration of supplemental doses in stressful situations.

OBJECTIVE


 We aimed to assess the prevalence of glucocorticoid-induced adrenal insufficiency in patients treated with only 5 mg prednisolone daily.

meaniciency in panemic treates with emy emg presimeers as any.			
Patient Handling Today	Adam - has Addison's Disease	Robert - has Rheumatoid Arthritis	
Treatment	Hydrocortisone 10 + 5 + 5 mg/day	Prednisolone 5 mg/day (equivalent to hydrocortisone 20 mg/day)	
Steroid Emergency Card	+	+/-	
Patient education in adrenal crisis	+	_	
Stress doses	+	_	
Synacthen® test	At diagnosis	- (Maybe at withdrawal)	

RESULTS

 Of the 37 patients 11 (30%) had an insufficient adrenal response to the Synacthen® test.

 Adrenocorticotropic hormone (ACTH) levels were generally low within reference range. Adrenal Insufficiency: 30%



SUBJECTS AND MEASURES

SUBJECTS

 Patients with rheumatoid arthritis treated with 5 mg prednisolone/day for at least 6 months, included as part of a larger study.

MEASURES

- A 250 µg Synacthen® test was performed fasting, in the morning, after a mean prednisolone pause of 47 hours. P-cortisol was measured before and 30 min after Synacthen® injection.
- Cut-off for normal adrenal function was 30 min P-cortisol > 500 nmol/l as this is validated for our local cortisol assay[1].

Patient Characteristics		
Number of participants	37 (26 women)	
Mean age (range)	66 years (36-85 years)	
Mean duration of therapy (range)	108 months (6-336 months)	
 Prednisolone dose above 5 mg 1 month prior 2-3 month prior 4-6 months prior 	5 None 1 (7.5 mg) 5 (7.5-15 mg)	
Mean time since last prednisolone dose (range)	47 hours (36-96 hours)	
Number also on other glucocorticoids •intra-articular injections •intra-muscular injections •steroid cream	6 2 (paused 2-6 weeks) 3 (paused 1-6 weeks) 1 (paused several weeks)	

CONCLUSION

- We found adrenal insufficiency in approximately one third of patients treated with 5 mg prednisolone daily.
- Since the prednisolone treatment is often sustained for years in these patients, adrenal suppression is likely equally prolonged.
- It raises the question whether patients on long-term low-dose prednisolone treatment need to be handled with some of the same precautions as patients with verified adrenal insufficiency.
- Should Synacthen® tests be routinely performed in these patients?
- Low-dose prednisolone treated patients with adrenal insufficiency should receive supplemental doses during stress.

More awareness of adrenal insufficiency in long-term low-dose prednisolone treated patients is urgently needed

Patient Handling Tomorrow	Adam	Robert - has Rheumatoid Arthritis
Treatment	Hydrocortisone 10 + 5 + 5 mg/day	Prednisolone 5 mg/day (equivalent to hydrocortisone 20 mg/day)
Steroid Emergency Card	+	+
Patient education in adrenal crisis	+	+
Stress doses	+	+ If adrenal insufficiency
Synacthen® test	At diagnosis	At any suspicion + At routine intervals?

References:

[1] Klose M et al. J Clin Endocrinol Metab 2007; 92:1326-33

Conflicts of interest: none

Correspondence: stina.willemoes@borresen.eu







